GRI BIO INC最新发布的2a期临床试验基因表达数据取得突破性进展,该数据清晰表明在特发性肺纤维化治疗中,与纤维化进程和肺部组织修复相关的核心生物标志物呈现显著积极变化。研究结果揭示了实验疗法对疾病关键通路的影响,为后续临床开发提供了强有力的科学依据。
GRI BIO INC最新发布的2a期临床试验基因表达数据取得突破性进展,该数据清晰表明在特发性肺纤维化治疗中,与纤维化进程和肺部组织修复相关的核心生物标志物呈现显著积极变化。研究结果揭示了实验疗法对疾病关键通路的影响,为后续临床开发提供了强有力的科学依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.